Heterocyclic compound
The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
1. A method of inhibiting histone deacetylase 6 in a mammal, which comprises administering to the mammal an effective amount of a compound represented by formula (I) or a salt thereof:
wherein R 1 is an optionally substituted cyclic group, and R 2 is an optionally substituted cyclic group.
2. A method for treatment of Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia and parkinsonism linked to MAPT mutation (FTDP-17), frontotemporal dementia, Charcot-Marie-Tooth disease, peripheral neuropathy, amyotrophic lateral sclerosis (ALS) or cancer in a mammal, which comprises administering to the mammal an effective amount of a compound represented by formula (I) or a salt thereof:
wherein R 1 is an optionally substituted cyclic group, and R 2 is an optionally substituted cyclic group.